arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Tarsus Pharmaceuticals, Inc.

TARS Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$91.25
▲ +0.5% Today
as of Sep 4, 16:55 ET
Last 30 days +53.99% Jul 28 → Sep 04
$55.94 $65.29 $74.65 $84.01 $93.36 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$82.71
High
$91.53
Low
$81.07
Volume
$2M
Avg Vol
$703,050
Mkt Cap
$3.0B
P/E (TTM)
—
Beta
—
52w High
$91.53
52w Low
$48.20
Div Yield
—
Shares Out
$43M

Recent Press Releases & News last 60 days · 25 items

Sep 4 · 19:30 MT Newswires
Update: Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
Sep 4 · 13:08 MT Newswires
Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals
Sep 4 · 12:38 PR GlobeNewswire
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$48
$92
99% of range
Avg surprise (last 3)
+9.0%
Avg reaction (last 2)
-1.8%
0% positive
Latest IV / EM
65%
EM ±10.1% · $90 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.28$-1.00$-0.72$-0.44$-0.16 Actual $-0.88Actual $-1.17Actual $-1.28Actual $-1.01Actual $-0.88Actual $-0.61Actual $-0.64Est $-0.69Actual $-0.48Est $-0.33Actual $-0.30Actual $-0.16Est $-0.46Actual $-0.43 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-25M$27M$79M$131M$183M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.43 — — — — financials
Wed May 6, 2026Mar/2026 $-0.16 $-0.46 +65.2% +75.0% -0.4% earnings
Tue Sep 30, 2025Sep 2025 $-0.30 — — — — financials
Wed Aug 6, 2025Jun/2025 $-0.48 $-0.33 -45.5% — — earnings
Thu May 1, 2025Mar/2025 $-0.64 $-0.69 +7.2% — -3.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.61 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.88 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.01 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.28 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.17 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.88 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$174M$162M—$119M$103M$78M—$48M
Cost of revenue$12M$9M——$6M$5M——
Gross profit————————
Operating income$-20M$-6M—$-15M$-22M$-26M—$-25M
Net income$-19M$-7M—$-13M$-20M$-25M—$-23M
EPS (diluted)$-0.43$-0.16—$-0.30$-0.48$-0.64—$-0.61

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$205M$102M$184M$113M$97M$176M$95M$176M
Inventory$4M$5M$4M$4M$4M$3M$3M$3M
Total current assets$562M$537M$523M$502M$474M$481M$357M$357M
Total assets$611M$581M$562M$535M$495M$501M$377M$376M
Long-term debt$73M$73M$72M$72M$72M$72M$72M$72M
Total liabilities$264M$232M$219M$199M$162M$158M$152M$139M
Total equity$347M$349M$343M$335M$333M$342M$225M$237M

Implied volatility — last 90 days

44%86%128%169%211% Jun 07 — IV 65% · EM ±9.1%Jun 08 — IV 72% · EM ±9.6%Jun 09 — IV 80% · EM ±10.1%Jun 10 — IV 79% · EM ±9.3%Jun 11 — IV 81% · EM ±9.0%Jun 12 — IV 82% · EM ±8.4%Jun 15 — IV 114% · EM ±8.2%Jun 16 — IV 112% · EM ±6.6%Jun 17 — IV 195% · EM ±8.2%Jun 19 — IV 59% · EM ±13.0%Jun 22 — IV 63% · EM ±13.2%Jun 23 — IV 65% · EM ±13.2%Jun 24 — IV 59% · EM ±11.8%Jun 25 — IV 64% · EM ±12.6%Jun 26 — IV 67% · EM ±12.9%Jun 29 — IV 77% · EM ±13.7%Jun 30 — IV 80% · EM ±13.7%Jul 01 — IV 64% · EM ±10.7%Jul 02 — IV 90% · EM ±14.6%Jul 03 — IV 62% · EM ±9.7%Jul 06 — IV 63% · EM ±8.8%Jul 07 — IV 61% · EM ±8.0%Jul 08 — IV 71% · EM ±9.0%Jul 09 — IV 73% · EM ±8.6%Jul 10 — IV 84% · EM ±9.3%Jul 13 — IV 115% · EM ±9.6%Jul 14 — IV 121% · EM ±8.8%Jul 15 — IV 156% · EM ±9.2%Jul 16 — IV 212% · EM ±8.8%Jul 20 — IV 68% · EM ±16.0%Jul 21 — IV 58% · EM ±13.5%Jul 22 — IV 62% · EM ±14.3%Jul 23 — IV 62% · EM ±13.9%Jul 24 — IV 61% · EM ±13.5%Jul 27 — IV 68% · EM ±14.1%Jul 28 — IV 72% · EM ±14.8%Jul 29 — IV 64% · EM ±12.8%Jul 30 — IV 66% · EM ±12.9%Jul 31 — IV 61% · EM ±11.6%Aug 03 — IV 67% · EM ±11.9%Aug 04 — IV 73% · EM ±12.6%Aug 05 — IV 68% · EM ±11.4%Aug 06 — IV 52% · EM ±8.3%Aug 07 — IV 55% · EM ±8.6%Aug 10 — IV 59% · EM ±8.1%Aug 11 — IV 60% · EM ±7.9%Aug 12 — IV 62% · EM ±7.7%Aug 13 — IV 63% · EM ±7.5%Aug 14 — IV 72% · EM ±7.9%Aug 17 — IV 90% · EM ±7.5%Aug 18 — IV 72% · EM ±5.2%Aug 19 — IV 131% · EM ±7.8%Aug 20 — IV 188% · EM ±7.8%Aug 24 — IV 58% · EM ±12.1%Aug 25 — IV 50% · EM ±10.2%Aug 26 — IV 49% · EM ±9.8%Aug 27 — IV 46% · EM ±9.0%Aug 28 — IV 47% · EM ±9.0%Aug 31 — IV 50% · EM ±8.9%Sep 01 — IV 49% · EM ±8.5%Sep 02 — IV 60% · EM ±10.1%Sep 03 — IV 45% · EM ±7.3%Sep 04 — IV 65% · EM ±10.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in